GI Innovation
June 24, 2026
Theater 1
Type: Company Presentation
Focus Area:
Oncology
GI Innovation is a South Korean biotech company founded in 2017 with the mission to improve human health by developing innovative biologics. Publicly listed since 2023, GI Innovation employs 90 staff and has achieved three major out-licensing deals for its immunological therapies with a cumulative deal value of USD $2.5B. The company is developing GI-102, a targeted immune checkpoint inhibitor and effector cell stimulator, with clinical collaboration agreements underway with Johnson & Johnson and MSD (Merck & Co.).
Company HQ City:
Seoul
Company HQ State:
Seoul
Company HQ Country:
Korea, Republic of
Year Founded:
2017
Lead Product in Development:
GI-102, a bispecific immunocytokine in Phase 2 development for solid tumors
CEO
Myoung Ho Jang
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
4
Exchange
KOSDAQ
Ticker
358570
When you expect your next catalyst update?
Q3, 2026
What is your next catalyst (value inflection) update?
Clinical data update for GI-102
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}